Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fenofibrate
Drug ID BADD_D00873
Description Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]
Indications and Usage Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia.[L8588,L8591] Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.[L8588,L8591]
Marketing Status approved
ATC Code C10AB05
DrugBank ID DB01039
KEGG ID D00565
MeSH ID D011345
PubChem ID 3339
TTD Drug ID D07XGR
NDC Product Code 11014-0132; 11722-065; 17337-0019; 58175-0348; 0074-3173; 13668-439; 31722-595; 0115-5522; 42385-950; 50090-6227; 51079-599; 55111-349; 60505-3121; 60687-629; 60760-318; 62332-361; 62332-538; 63304-444; 68180-131; 68180-231; 68462-580; 68462-582; 69238-1263; 71205-050; 71205-190; 71205-666; 71205-949; 0904-7161; 66064-1006; 16714-740; 27437-109; 0115-0522; 0115-5511; 42385-951; 42858-200; 43547-431; 50090-3044; 63304-448; 68071-1712; 70518-2768; 71335-1701; 72789-310; 13668-440; 46708-085; 51407-092; 51407-204; 51655-234; 59651-203; 60687-666; 63187-640; 63304-901; 0378-7100; 68180-389; 68788-8106; 69844-008; 71335-1286; 71335-1292; 71335-2016; 59651-576; 60219-5522; 62332-086; 62332-554; 62559-305; 63187-940; 63304-449; 0378-4391; 68462-581; 69097-894; 69238-1261; 69367-270; 70756-214; 71205-366; 71335-0741; 71335-0891; 82009-060; 11014-0131; 17337-0410; 27437-110; 35561-345; 42291-289; 42385-936; 42858-454; 42858-660; 43975-306; 46708-555; 51407-205; 59651-201; 60687-713; 62332-084; 63187-681; 0378-3066; 68071-2587; 68180-746; 68682-490; 69238-1260; 69315-290; 69367-254; 69844-013; 46708-084; 46708-361; 46708-554; 50268-312; 50268-338; 55700-876; 60219-5511; 60687-655; 62332-360; 62559-461; 68071-2812; 68788-7816; 69097-458; 69367-269; 69844-009; 70518-2349; 0615-8270; 65862-768; 68294-0001; 16714-741; 27241-120; 31722-596; 35561-346; 0115-0511; 42385-935; 42858-067; 46708-086; 46708-350; 46708-360; 50090-6120; 51407-094; 51655-433; 51655-856; 62332-539; 63304-443; 63629-1100; 63629-1101; 63629-9474; 0378-4390; 65862-769; 68071-2540; 68071-2686; 68788-7932; 69097-895; 69844-012; 17337-0430; 0904-7128; 59349-0018; 65977-0074; 16714-739; 35561-347; 0115-0533; 42291-427; 43353-001; 43353-272; 50090-1275; 50090-4698; 50090-5854; 51079-608; 59651-202; 62559-306; 63187-760; 63304-900; 0378-7101; 68012-490; 68084-328; 68180-232; 68180-388; 69315-288; 70934-977; 13672-020; 53747-033; 70966-0021; 13668-438; 27241-117; 27437-108; 42291-290; 43975-305; 43975-444; 51407-091; 60505-3120; 60687-618; 62332-085; 62332-351; 62559-460; 63629-7213; 0378-3065; 68084-827; 68180-130; 69097-896; 69315-287; 69367-268; 70518-2907; 70518-2947; 70518-3370; 71335-0872; 71610-027; 0074-3189; 27241-116; 27241-119; 43353-898; 43598-910; 50090-5244; 51407-090; 55111-395; 62332-350; 62332-555; 63629-1099; 63629-2505; 68012-495; 68084-329; 68682-495; 69097-459; 69238-1262; 69315-289; 70756-215; 71335-1756; 49452-3101; 68543-3173; 68543-3189; 27241-118; 42858-134; 43547-430; 43598-909; 46708-351; 50090-2899; 50090-5796; 50268-313; 51407-093; 51655-009; 51655-554; 59651-575
UNII U202363UOS
Synonyms Fenofibrate | Phenofibrate | Procetofene | Procetofen | Apo-Feno-Micro | Apo Feno Micro | Apo-Fenofibrate | Apo Fenofibrate | CiL | Controlip | durafenat | Fenobeta | Fenofanton | Fenofibrat AbZ | Fenofibrat AL | Fenofibrat AZU | AZU, Fenofibrat | Fenofibrat Heumann | Heumann, Fenofibrat | Fenofibrat Hexal | Hexal, Fenofibrat | Fenofibrat Stada | Stada, Fenofibrat | fenofibrat von ct | Fenofibrat-ratiopharm | Fenofibrat ratiopharm | Fénofibrate MSD | Gen-Fenofibrate | Gen Fenofibrate | LF-178 | LF 178 | LF178 | Lipanthyl | Lipantil | Fenofibrat FPh | Lipidil | Secalip | Supralip | Fénofibrate Debat | Debat, Fénofibrate | Lipidil-Ter | Lipidil Ter | Liparison | Livesan | Lofibra | MTW-Fenofibrat | MTW Fenofibrat | Novo-Fenofibrate | Novo Fenofibrate | Nu-Fenofibrate | Nu Fenofibrate | PMS-Fenofibrate Micro | PMS Fenofibrate Micro | Tricor | Normalip | Antara Micronized Procetofen | Micronized Procetofen, Antara | Procetofen, Antara Micronized
Chemical Information
Molecular Formula C20H21ClO4
CAS Registry Number 49562-28-9
SMILES CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Benign prostatic hyperplasia21.04.02.0010.000039%Not Available
Bladder pain20.02.02.001--Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood bilirubin increased13.03.04.018--
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood lactate dehydrogenase increased13.04.02.002--
Blood urea increased13.13.01.006--Not Available
Blood uric acid increased13.02.04.001--Not Available
Body temperature increased13.15.01.001--Not Available
Bone disorder15.02.04.004--Not Available
Breast feeding26.05.01.001--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Burning sensation17.02.06.001; 08.01.09.0290.000059%Not Available
Bursitis12.04.03.010; 15.04.01.001--Not Available
Calculus urinary20.04.03.002--Not Available
Cardiac failure congestive02.05.01.0020.000059%Not Available
Cardiomegaly02.04.02.0010.000039%Not Available
Cardiovascular disorder02.11.01.010; 24.03.02.009--Not Available
Cataract06.06.01.001--
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.002--Not Available
Chills15.05.03.016; 08.01.09.0010.000126%
Cholecystitis09.03.01.001--
Cholelithiasis09.03.01.0020.000059%Not Available
Cholestasis09.01.01.0010.000118%Not Available
Chromaturia20.02.01.0020.000138%
Cirrhosis alcoholic09.01.04.005--Not Available
Colitis07.08.01.001--
Condition aggravated08.01.03.0040.000363%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene